Takeda to acquire maverick therapeutics to advance t-cell engager therapies for solid tumors and expand novel immuno-oncology portfolio

Osaka, japan & brisbane, calif.--(business wire)--takeda exercised its option to acquire maverick, expanding its immuno-oncology portfolio with two development candidates and a t-cell engager platform

TAK Ratings Summary

TAK Quant Ranking